Last Update 04 Feb 26

Fair value Increased 0.67%

ONC: Hematology And Solid Tumor Pipeline Progress Will Drive Future Upside

Analysts lifted their price target for BeOne Medicines to about $404, up roughly $3, citing increased conviction in the value of its hematology and solid tumor pipeline, which is reflected in a slightly higher assumed future P/E multiple.

Analyst Commentary

Recent research updates on BeOne Medicines cluster around a similar theme: bullish analysts are raising price targets and citing comfort with both the hematology and solid tumor franchises, while also highlighting execution risks that investors should keep in mind.

Bullish Takeaways

Bullish analysts argue that BeOne's hematology pipeline, including chronic lymphocytic leukemia assets such as sonrotoclax, is underappreciated by the market. They view this as a key support for higher valuation multiples.
Several research notes point to Brukinsa results that topped estimates and to raised total revenue guidance to US$5.1b to US$5.3b. Analysts interpret this as evidence of solid commercial execution that can support current and higher P/E assumptions.
Updates on Ziihera and the phase III HORIZON GEA program, alongside Tevimbra combinations, are viewed as adding incremental upside to BeOne's solid tumor story. Analysts link these developments to higher price targets in the US$390 to US$420 range.
Analysts who have interacted with management highlight confidence in BeOne's ability to serve the full spectrum of B cell malignancies. They argue that this breadth positions the company for durable growth across multiple indications rather than relying on a single product.

Bearish Takeaways

Even bullish analysts note that BeOne's elevated price targets assume successful execution on late stage programs such as Ziihera plus Tevimbra in first line HER2 positive GEA. Any delay in approvals or data readouts could therefore pressure valuation.
The expectation for an "exciting" 2025 ASH conference and further data in 2026 sets a high bar. Weaker than expected clinical updates could challenge the current enthusiasm reflected in the US$400 plus target range.
BeOne's aim to dominate B cell malignancies depends on continued competitive positioning against existing and future therapies. Analysts implicitly acknowledge that changes in treatment standards could affect long term growth assumptions.
With much of the analyst thesis tied to a broad pipeline across hematology and solid tumors, any setbacks in key programs or commercial trends for Brukinsa would likely have an outsized impact on the premium multiples currently used in models.

What's in the News

BeOne reported positive top line Phase 3 HERIZON GEA 01 results for ZIIHERA in HER2 positive gastroesophageal adenocarcinoma, with both ZIIHERA plus TEVIMBRA and ZIIHERA plus chemotherapy showing clinically meaningful and highly statistically significant progression free survival benefits versus trastuzumab plus chemotherapy, and the TEVIMBRA arm also showing statistically significant overall survival benefit (Key Developments).
Full Phase 3 HERIZON GEA 01 data for ZIIHERA plus chemotherapy with and without TEVIMBRA, including the first interim overall survival analysis, are planned for a Late Breaking Oral Presentation at ASCO GI 2026. BeOne also intends to submit supplemental biologics applications to the U.S. FDA and China NMPA and to pursue further regulatory filings across its territories (Key Developments).
Health Canada granted a Notice of Compliance for TEVIMBRA with gemcitabine and cisplatin as first line treatment for recurrent or metastatic nasopharyngeal carcinoma, based on Phase 3 RATIONALE 309, where the regimen met the primary endpoint and showed a 48% reduction in the risk of disease progression or death versus placebo plus chemotherapy (Key Developments).
The U.S. FDA accepted and granted Priority Review to the New Drug Application for sonrotoclax in relapsed or refractory mantle cell lymphoma after BTK inhibitor treatment. BeOne is also pursuing parallel reviews through Project Orbis and additional submissions in China and other regions for mantle cell lymphoma and CLL/SLL (Key Developments).
BeOne updated full year 2025 guidance and now expects total revenue to be in a range of US$5.1b to US$5.3b, compared with prior guidance of US$5.0b to US$5.3b (Key Developments).

Valuation Changes

Fair Value: updated modestly from US$401.52 to US$404.19 per share; this reflects a slightly higher appraisal of BeOne Medicines based on the latest inputs.
Discount Rate: adjusted marginally from 6.75% to 6.80%; this indicates a small change in the required rate of return used in the valuation model.
Revenue Growth: revised slightly from 17.20% to 17.17%; this shows a very small tweak to long term top line growth assumptions.
Net Profit Margin: moved from 19.41% to 19.17%; this is a modest reduction in the assumed long run profitability level.
Future P/E: increased from 38.67x to 39.49x; this points to a somewhat higher multiple applied to BeOne Medicines' projected earnings.

15 views

Key Takeaways

Rapid commercial expansion and innovative therapies drive sustained growth, with a strong product pipeline supporting future revenue and margin improvement.
Operational efficiencies and new product formulations position the company for enhanced profitability and resilience against external cost pressures.
Reliance on a narrow product base, intensifying competition, regulatory pressures, and global supply risks threaten revenue, margins, and long-term profitability.

Catalysts

About BeOne Medicines

An oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.What are the underlying business or industry changes driving this perspective?

BeOne's strong revenue growth (41% YoY in Q2; updated full-year guidance of $5–$5.3B) is underpinned by rapid demand expansion for differentiated, best-in-class oncology therapies like BRUKINSA-supported by a growing, aging population and increased global healthcare spending, both of which point to a sustainably expanding addressable market and future revenue growth.
The company's robust pipeline, including multiple late-stage oncology assets (over 20 Phase III trials and >10 proof-of-concept readouts expected in the next 18 months), leverages internal R&D capabilities and the GlueXplorer™ platform to rapidly develop targeted, personalized medicines-well-aligned with the shift toward precision therapeutics, supporting long-term earnings and margin expansion as products commercialize.
BeOne's rapid commercial expansion into new international markets and increasing product launches (with 87% Europe revenue growth and "Rest of World" up 168%, plus >75 countries approved), combined with product mix improvements and new formulations like BRUKINSA's tablet, provide catalysts for incremental revenue and continued gross margin improvement.
Management's focus on operational efficiencies-evidenced by improved gross margins (from 85% to 87%), cost of goods reduction initiatives (tablet formulation), and regionalized supply chains-directly supports future net margin expansion and free cash flow, helping address concerns over sustainability and external cost pressures.
Value inflection points are approaching as multiple pivotal trial readouts and global filings (for sonrotoclax, BTK CDAC, and solid tumor assets) are expected by 2026, lining up with increased adoption and reimbursement potential driven by broader healthcare investment and potential upside to future earnings as breakthrough therapies achieve approval.

BeOne Medicines Earnings and Revenue Growth

BeOne Medicines Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming BeOne Medicines's revenue will grow by 18.6% annually over the next 3 years.
Analysts assume that profit margins will increase from -3.9% today to 17.5% in 3 years time.
Analysts expect earnings to reach $1.3 billion (and earnings per share of $10.62) by about September 2028, up from $-177.6 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $2.0 billion in earnings, and the most bearish expecting $147.8 million.
In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 44.0x on those 2028 earnings, up from -208.3x today. This future PE is greater than the current PE for the US Biotechs industry at 15.5x.
Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 6.45%, as per the Simply Wall St company report.

BeOne Medicines Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

Intensifying competition from both larger pharmaceutical companies and emerging biotechs in the BTK inhibitor and protein degradation therapy space could erode BeOne's market share, forcing more aggressive discounting and pricing concessions; this threatens future revenue growth and profit margins as seen by competition "aggressively discounting" and ongoing focus on maintaining "broad access" in the U.S.
Heavy revenue concentration in BRUKINSA and the CLL franchise exposes BeOne to single-product risk; potential clinical trial setbacks, regulatory delays, or new entrants (such as pirtobrutinib or alternative treatment modalities) could lead to volatile earnings and substantial revenue declines if key assets underperform or lose competitive edge.
Regulatory and policy headwinds-such as U.S. drug price negotiations, tighter controls under Medicare Part D, and potential new tariffs on pharmaceutical imports-could compress net margins and restrict net pricing flexibility in key markets, undermining earnings growth even in the face of volume gains.
High and rising R&D expenditures, coupled with the challenges of late-phase clinical trial execution and a rapidly expanding global pipeline, risk sustained operating expense growth; delays in advancing or commercializing new drugs (as noted in the Phase III trial timing for new assets) could threaten long-term profitability and dampen future free cash flow.
Geopolitical instability and global supply chain risks threaten operational efficiency, particularly with exposure to potential U.S. tariffs and reliance on international manufacturing; unforeseen cost increases or distribution disruptions may impair gross margins and impact the steady flow of life-saving medicines, resulting in downward pressure on net income.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $363.3 for BeOne Medicines based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $563.0, and the most bearish reporting a price target of just $250.0.
In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $7.6 billion, earnings will come to $1.3 billion, and it would be trading on a PE ratio of 44.0x, assuming you use a discount rate of 6.4%.
Given the current share price of $336.26, the analyst price target of $363.3 is 7.4% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on BeOne Medicines?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

ONC: Pivotal Oncology Trial Data Will Drive Future Upside Momentum